Clinical Diligence Platform for Neurodegenerative Drug Programs
CNS Trials,
Decoded by AI
Analyze CNS clinical trials before they fail. Built for biotech investors, BD teams, and CNS research groups evaluating neurodegenerative pipelines.
Built for the future of clinical intelligence.
Genivra models Phase II transition risk using imaging and biomarker validation signals across neurodegenerative programs.
Neural Data Mapping
Automatically categorize and link complex neurobiological data points with 99.8% accuracy using our LLM-driven parser.
Predictive Outcomes
Simulate trial results based on historical cohorts to identify potential bottlenecks before they impact your timeline.
Immutable Compliance
Enterprise-grade security with audit trails logged on a private ledger, ensuring absolute data integrity and regulatory readiness.
Automated Reporting
Generate publication-ready reports and visualization suites with a single click, formatted for FDA and EMA submissions.
Ready to accelerate your research?
Join leading biotech teams who trust Genivra for their critical intelligence needs.